Caprock Group LLC Buys Shares of 44,359 Tandem Diabetes Care, Inc. $TNDM

Caprock Group LLC purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 44,359 shares of the medical device company’s stock, valued at approximately $555,000.

A number of other hedge funds also recently made changes to their positions in TNDM. Acadian Asset Management LLC lifted its holdings in Tandem Diabetes Care by 54.0% in the second quarter. Acadian Asset Management LLC now owns 358,516 shares of the medical device company’s stock worth $6,676,000 after purchasing an additional 125,644 shares during the period. Sector Gamma AS boosted its holdings in shares of Tandem Diabetes Care by 28.0% in the third quarter. Sector Gamma AS now owns 269,542 shares of the medical device company’s stock valued at $3,272,000 after acquiring an additional 59,019 shares in the last quarter. Champlain Investment Partners LLC increased its stake in shares of Tandem Diabetes Care by 6.3% during the second quarter. Champlain Investment Partners LLC now owns 1,455,123 shares of the medical device company’s stock valued at $27,123,000 after acquiring an additional 86,235 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in Tandem Diabetes Care by 122.2% during the second quarter. Dynamic Technology Lab Private Ltd now owns 26,143 shares of the medical device company’s stock worth $488,000 after purchasing an additional 14,377 shares in the last quarter. Finally, Paradice Investment Management LLC raised its holdings in Tandem Diabetes Care by 7.1% during the second quarter. Paradice Investment Management LLC now owns 1,767,179 shares of the medical device company’s stock worth $32,940,000 after purchasing an additional 117,272 shares in the last quarter.

Tandem Diabetes Care Trading Down 0.6%

Tandem Diabetes Care stock opened at $18.84 on Wednesday. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $35.12. The company has a debt-to-equity ratio of 2.33, a quick ratio of 1.90 and a current ratio of 2.44. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.18 and a beta of 1.68. The company has a 50 day moving average price of $20.95 and a 200 day moving average price of $16.92.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TNDM shares. Citigroup increased their price target on Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Stifel Nicolaus lifted their target price on Tandem Diabetes Care from $16.00 to $20.00 and gave the stock a “hold” rating in a report on Wednesday, February 4th. Mizuho upped their price target on shares of Tandem Diabetes Care from $18.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, December 17th. Truist Financial set a $24.00 price objective on shares of Tandem Diabetes Care and gave the stock a “hold” rating in a research note on Thursday, December 18th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 target price on shares of Tandem Diabetes Care in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $24.35.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.